Latest News for: asco

Edit

K36 Therapeutics Highlights First-in-Human KTX-2001 Prostate Cancer Study Design at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2026

PR Newswire 24 Feb 2026
ASCO Genitourinary Cancers Symposium, February 26–28, 2026 Trial in Progress Poster Details. ... abstract can be found at ASCO GU Meeting Website. https.//asco.org/abstracts-presentations/256624.
Edit

Kyntra Bio Announces Positive Data from the Investigator-Sponsored Phase 1b/2 Study of FG-3246 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer to Be Presented at ASCO GU 2026 (Kyntra Bio Inc)

Public Technologies 23 Feb 2026
... Phase 1b/2 study will be presented at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026 in San Francisco, CA.
Edit

Blue Earth Diagnostics to Highlight New POSLUMA® (Flotufolastat F 18) Study Results in Prostate Cancer at the 2026 ASCO Genitourinary Symposium (ASCO GU)

PR Newswire 18 Feb 2026
Blue Earth Diagnostics invites participants at ASCO GU to attend the presentations below ... For full session details and scientific presentation listings, please see the ASCO GU online program here.
Edit

ASCO GU 2026: Merck and Protara Poised to Disrupt Bladder and Kidney Cancer Standards

The Call 16 Feb 2026
CG Oncology is also presenting data at ASCO GU from its CORE-008 trial, evaluating cretostimogene in BCG-naïve patients ... The data emerging from ASCO GU 2026 underscores a broader trend in oncology.
Edit

Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU ...

Enid News & Eagle 12 Feb 2026
RAHWAY, N.J.--(BUSINESS WIRE)--Feb 12, 2026-- ... .
Edit

ASCO and Conexiant Launch ASCO AI in Oncology, a Premium Digital Destination Connecting Brands with Oncology Professionals Exploring AI in Cancer Care

PR Newswire 10 Feb 2026
ASCO AI in Oncology ... ASCO AI in Oncology features ASCO-sourced intelligence, expert perspectives, and practitioner-driven insight ... ASCO is uniquely positioned to amplify this ... About ASCO AI in Oncology.
Edit

QureBio Ltd. to Present at ASCO 2026 its Q-1802 Phase II Clinical Results

The Citizens 29 Jan 2026
... today revealed in 2026 ASCO abstract submission about .
Edit

Parker Institute for Cancer Immunotherapy Collaborates with Conquer Cancer and ASCO to Support Promising Cancer Research

Independent Record 29 Jan 2026
Endowed Young Investigator Award will fund oncologists conducting cancer research during the early stages of their careers to encourage and promote high quality immunotherapy research ... .
Edit

Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ

PR Newswire 13 Jan 2026
398) at the 2026 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2026) ... The results presented at ASCO GI 2026 focus on the GC/GEJ cohort ... The presentation at ASCO GI 2026 highlights Immunofoco's ...
Edit

ACCENT DATA PRESENTED AT 2026 ASCO GASTROINTESTINAL CANCER SYMPOSIUM (Amplia Therapeutics Ltd)

Public Technologies 12 Jan 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 128847689) .
Edit

ASCO-GI: Incyte Presentation (Incyte Corporation)

Public Technologies 12 Jan 2026
). The text version of this document is not available ... Disclaimer ... (noodl. 128853138) .
Edit

Actuate Therapeutics Reports Positive Follow-Up Data from its Randomized Controlled Phase 2 Trial Demonstrating Extended Long-Term Overall Survival Benefit with Elraglusib Plus Chemotherapy for Metastatic Pancreatic Cancer in Oral Presentation at ASCO GI 2026 (Actuate Therapeutics Inc)

Public Technologies 12 Jan 2026
... for metastatic pancreatic cancer were featured in oral and poster presentations at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) on January 9, 2026.
Edit

Alligator Bioscience to Present New OPTIMIZE-1 Data on Mitazalimab at ASCO Gastrointestinal Cancers Symposium 2026

Pharmiweb 09 Jan 2026
... untreated metastatic pancreatic ductal adenocarcinoma (mPDAC) will be presented at the ASCO Gastrointestinal Cancers Symposium (ASCO GI) in San Francisco, CA, taking place 8-11 January 2026.
Edit

Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium (Form 8-K) (Autonomix Medical Inc)

Public Technologies 09 Jan 2026
Autonomix Showcases Compelling PoC Study Clinical Data Showing Rapid and Durable Pain Relief Across All Disease Stages of Pancreatic Cancer at the 2026 ASCO Gastrointestinal (GI) Cancers Symposium.
Edit

Phanes Therapeutics Announces Positive Phase 2 Results of Spevatamig (PT886) in Combination with Chemotherapy in Frontline (1L) Treatment of Metastatic PDAC at ASCO GI 2026

PR Newswire 09 Jan 2026
The data was presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) 2026; Abstract #709 ... Phanes' data of spevatamig featured at ASCO GI 2026 can be found here.

Article Search

tools
×
×
×
×